Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
Conditions: Hepatocellular Carcinoma; Liver Transplantation Intervention: Drug: Camrelizumab treatment Sponsor: Third Affiliated Hospital, Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver | Liver Cancer | Liver Transplant | Research | Transplants | Urology & Nephrology